恩瑞格治疗铁质积聚的疗效怎么样呢？

It is used to treat chronic iron overload in patients with beta-thalassemia older than 6 years old due to frequent blood transfusions (monthly administration of concentrated red blood cells ≥ 7 mL/kg); for children under 6 years old and patients with iron overload caused by other transfusion-dependent diseases.

So, how effective is Enrig in treating iron accumulation?

Therapeutic effects of Enrige in treating iron accumulation:

Study the iron-removing efficacy and safety of Enrig in patients with aplastic anemia (AA) associated with iron overload. 

Methods: The iron-removing efficacy of 64 AA patients with iron overload after 12 months of treatment with Enrige was analyzed, and the safety was evaluated. Results The starting dose of Enriga in all patients was 20.0 mg·kg-1·d-1, and the average dose was (18.6±3.60) mg·kg-1·d-1. After 12 months of treatment, the median serum ferritin (SF) level dropped from the baseline of 4924 (2718~6765) μg/L (64 cases) to 3036 (1474~5551) μg/L (23 cases), a decrease of 38%, and the median SF reduction was 651 (126~2). 125) μg/L; the median SF level of 23 patients who completed 12 months of treatment dropped from the baseline of 5271 (3420~8278) μg/L to 3036 (1474~5551) μg/L, a decrease of 42%, and the median SF reduction was 1167 (580~4806) μg/L. 

Increased serum creatinine (40.98%) and gastrointestinal discomfort (40.98%) were the main adverse events during treatment with Enriga, followed by increased liver aminotransferases (ALT: 21.31%; AST: 13.11%) and proteinuria (24.59%). The increase in serum creatinine is reversible and non-progressive. 

For the 38 patients who were concurrently taking cyclosporine, 12 patients (31.8%) had creatinine values >the upper limit of normal (ULN) for 2 consecutive times, 10 patients (26.3%) had creatinine values >1.33 baseline value for 2 consecutive times, and only 1 patient (2.6%) had serum creatinine that increased beyond the 1.33 baseline value and exceeded the ULN. For AST and ALT, no patient throughout the study had two post-baseline values ​​>5×ULN or >10×ULN. For patients with baseline PLT levels below 50 × 109/L, median PLT did not decrease during treatment with Enriga.

Conclusion: Treatment of AA patients with iron overload can achieve good iron removal efficacy, the drug is well tolerated, and there are no clinically uncontrollable serious adverse events.